Short Interest in vTv Therapeutics Inc. (NASDAQ:VTVT) Decreases By 43.7%

vTv Therapeutics Inc. (NASDAQ:VTVT) was the recipient of a large drop in short interest during the month of March. As of March 31st, there was short interest totalling 32,200 shares, a drop of 43.7% from the March 15th total of 57,200 shares. Approximately 6.1% of the company’s shares are sold short. Based on an average trading volume of 73,400 shares, the days-to-cover ratio is currently 0.4 days.

vTv Therapeutics Price Performance

Shares of VTVT opened at $25.41 on Friday. The firm has a market capitalization of $76.48 million, a price-to-earnings ratio of -2.52 and a beta of 0.56. The company has a 50-day moving average of $16.70 and a 200 day moving average of $14.25. vTv Therapeutics has a 1-year low of $7.38 and a 1-year high of $39.60.

vTv Therapeutics (NASDAQ:VTVT) last posted its earnings results on Wednesday, March 13th. The biotechnology company reported ($1.67) EPS for the quarter.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of VTVT. Millennium Management LLC grew its position in vTv Therapeutics by 12.0% during the 2nd quarter. Millennium Management LLC now owns 138,683 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 14,845 shares during the last quarter. State Street Corp raised its position in vTv Therapeutics by 268.7% during the second quarter. State Street Corp now owns 206,145 shares of the biotechnology company’s stock worth $155,000 after acquiring an additional 150,228 shares during the period. Prudential Financial Inc. acquired a new position in vTv Therapeutics during the second quarter worth $30,000. Finally, Pathstone Family Office LLC acquired a new position in vTv Therapeutics during the third quarter worth $116,000. Hedge funds and other institutional investors own 17.51% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com upgraded shares of vTv Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, March 14th.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company's lead drug candidate is TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis.